XOMA Corporation (XOMA)
USD 19.49
(-1.62%)
USD 19.49
(-1.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 234.3 Million USD | 66.9% |
| 2022 | 140.38 Million USD | -15.72% |
| 2021 | 166.56 Million USD | 32.95% |
| 2020 | 125.28 Million USD | 30.88% |
| 2019 | 95.72 Million USD | 50.07% |
| 2018 | 63.78 Million USD | 41.95% |
| 2017 | 44.93 Million USD | 56.69% |
| 2016 | 28.67 Million USD | -61.7% |
| 2015 | 74.88 Million USD | -16.46% |
| 2014 | 89.63 Million USD | -33.5% |
| 2013 | 134.78 Million USD | 27.54% |
| 2012 | 105.67 Million USD | 35.42% |
| 2011 | 78.03 Million USD | 5.1% |
| 2010 | 74.25 Million USD | 40.56% |
| 2009 | 52.82 Million USD | -21.36% |
| 2008 | 67.17 Million USD | -20.8% |
| 2007 | 84.81 Million USD | -7.28% |
| 2006 | 91.47 Million USD | 26.04% |
| 2005 | 72.57 Million USD | 56.89% |
| 2004 | 46.26 Million USD | -61.08% |
| 2003 | 118.85 Million USD | 65.57% |
| 2002 | 71.78 Million USD | -16.64% |
| 2001 | 86.1 Million USD | 90.45% |
| 2000 | 45.21 Million USD | 59.76% |
| 1999 | 28.3 Million USD | -24.13% |
| 1998 | 37.3 Million USD | -42.44% |
| 1997 | 64.8 Million USD | 12.31% |
| 1996 | 57.7 Million USD | 41.08% |
| 1995 | 40.9 Million USD | -34.46% |
| 1994 | 62.4 Million USD | -33.69% |
| 1993 | 94.1 Million USD | -13.91% |
| 1992 | 109.3 Million USD | -29.16% |
| 1991 | 154.3 Million USD | 59.07% |
| 1990 | 97 Million USD | -12.22% |
| 1989 | 110.5 Million USD | 100.91% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 243.28 Million USD | 10.87% |
| 2024 Q1 | 219.42 Million USD | -6.35% |
| 2023 FY | 234.3 Million USD | 66.9% |
| 2023 Q1 | 133.66 Million USD | -4.79% |
| 2023 Q2 | 125.66 Million USD | -5.99% |
| 2023 Q3 | 124.09 Million USD | -1.25% |
| 2023 Q4 | 234.3 Million USD | 88.81% |
| 2022 Q4 | 140.38 Million USD | -3.93% |
| 2022 Q2 | 154.22 Million USD | -3.1% |
| 2022 Q1 | 159.16 Million USD | -4.44% |
| 2022 FY | 140.38 Million USD | -15.72% |
| 2022 Q3 | 146.13 Million USD | -5.25% |
| 2021 Q3 | 130.5 Million USD | -3.87% |
| 2021 FY | 166.56 Million USD | 32.95% |
| 2021 Q1 | 119.89 Million USD | -4.3% |
| 2021 Q4 | 166.56 Million USD | 27.63% |
| 2021 Q2 | 135.75 Million USD | 13.23% |
| 2020 Q2 | 87.85 Million USD | -4.29% |
| 2020 FY | 125.28 Million USD | 30.88% |
| 2020 Q3 | 85.72 Million USD | -2.42% |
| 2020 Q4 | 125.28 Million USD | 46.14% |
| 2020 Q1 | 91.79 Million USD | -4.11% |
| 2019 FY | 95.72 Million USD | 50.07% |
| 2019 Q3 | 86.09 Million USD | 9.91% |
| 2019 Q2 | 78.33 Million USD | 3.43% |
| 2019 Q4 | 95.72 Million USD | 11.18% |
| 2019 Q1 | 75.73 Million USD | 18.73% |
| 2018 FY | 63.78 Million USD | 41.95% |
| 2018 Q1 | 43.31 Million USD | -3.61% |
| 2018 Q4 | 63.78 Million USD | 38.18% |
| 2018 Q3 | 46.16 Million USD | 12.0% |
| 2018 Q2 | 41.21 Million USD | -4.84% |
| 2017 Q4 | 44.93 Million USD | -9.61% |
| 2017 FY | 44.93 Million USD | 56.69% |
| 2017 Q1 | 22.52 Million USD | -21.44% |
| 2017 Q2 | 24.14 Million USD | 7.17% |
| 2017 Q3 | 49.71 Million USD | 105.88% |
| 2016 Q1 | 52.6 Million USD | -29.74% |
| 2016 Q2 | 38.56 Million USD | -26.69% |
| 2016 Q4 | 28.67 Million USD | 16.14% |
| 2016 Q3 | 24.69 Million USD | -35.98% |
| 2016 FY | 28.67 Million USD | -61.7% |
| 2015 Q4 | 74.88 Million USD | -5.25% |
| 2015 FY | 74.88 Million USD | -16.46% |
| 2015 Q3 | 79.02 Million USD | 29.89% |
| 2015 Q2 | 60.84 Million USD | -22.07% |
| 2015 Q1 | 78.06 Million USD | -12.9% |
| 2014 Q1 | 107.62 Million USD | -20.15% |
| 2014 Q2 | 89.92 Million USD | -16.45% |
| 2014 Q3 | 70.93 Million USD | -21.12% |
| 2014 FY | 89.63 Million USD | -33.5% |
| 2014 Q4 | 89.63 Million USD | 26.36% |
| 2013 Q1 | 88.94 Million USD | -15.83% |
| 2013 Q4 | 134.78 Million USD | 48.1% |
| 2013 Q2 | 76.94 Million USD | -13.49% |
| 2013 Q3 | 91 Million USD | 18.27% |
| 2013 FY | 134.78 Million USD | 27.54% |
| 2012 Q2 | 85.91 Million USD | -15.2% |
| 2012 Q4 | 105.67 Million USD | 33.17% |
| 2012 Q3 | 79.35 Million USD | -7.64% |
| 2012 FY | 105.67 Million USD | 35.42% |
| 2012 Q1 | 101.32 Million USD | 29.84% |
| 2011 FY | 78.03 Million USD | 5.1% |
| 2011 Q1 | 82.47 Million USD | 11.08% |
| 2011 Q2 | 79.59 Million USD | -3.49% |
| 2011 Q3 | 77.18 Million USD | -3.03% |
| 2011 Q4 | 78.03 Million USD | 1.1% |
| 2010 Q3 | 43 Million USD | 6.3% |
| 2010 Q4 | 74.25 Million USD | 72.68% |
| 2010 Q1 | 56.69 Million USD | 7.33% |
| 2010 FY | 74.25 Million USD | 40.56% |
| 2010 Q2 | 40.45 Million USD | -28.65% |
| 2009 Q4 | 52.82 Million USD | -3.0% |
| 2009 Q1 | 72.93 Million USD | 8.57% |
| 2009 Q2 | 66.78 Million USD | -8.43% |
| 2009 Q3 | 54.45 Million USD | -18.46% |
| 2009 FY | 52.82 Million USD | -21.36% |
| 2008 Q3 | 64.47 Million USD | -19.05% |
| 2008 Q2 | 79.64 Million USD | 41.32% |
| 2008 Q1 | 56.35 Million USD | -33.56% |
| 2008 Q4 | 67.17 Million USD | 4.19% |
| 2008 FY | 67.17 Million USD | -20.8% |
| 2007 Q2 | 67.54 Million USD | -3.85% |
| 2007 Q4 | 84.81 Million USD | -6.19% |
| 2007 FY | 84.81 Million USD | -7.28% |
| 2007 Q3 | 90.41 Million USD | 33.85% |
| 2007 Q1 | 70.25 Million USD | -23.2% |
| 2006 Q3 | 56.59 Million USD | -15.41% |
| 2006 Q2 | 66.9 Million USD | -5.36% |
| 2006 Q1 | 70.69 Million USD | -2.6% |
| 2006 Q4 | 91.47 Million USD | 61.64% |
| 2006 FY | 91.47 Million USD | 26.04% |
| 2005 FY | 72.57 Million USD | 56.89% |
| 2005 Q1 | 87.11 Million USD | 88.32% |
| 2005 Q2 | 84.46 Million USD | -3.05% |
| 2005 Q3 | 74.02 Million USD | -12.35% |
| 2005 Q4 | 72.57 Million USD | -1.96% |
| 2004 FY | 46.26 Million USD | -61.08% |
| 2004 Q2 | 76.59 Million USD | -24.61% |
| 2004 Q3 | 58.93 Million USD | -23.06% |
| 2004 Q1 | 101.59 Million USD | -14.52% |
| 2004 Q4 | 46.26 Million USD | -21.51% |
| 2003 FY | 118.85 Million USD | 65.57% |
| 2003 Q1 | 62.17 Million USD | -13.38% |
| 2003 Q2 | 55.43 Million USD | -10.84% |
| 2003 Q3 | 114.92 Million USD | 107.29% |
| 2003 Q4 | 118.85 Million USD | 3.42% |
| 2002 Q2 | 78.6 Million USD | -6.39% |
| 2002 Q4 | 71.78 Million USD | 7.11% |
| 2002 FY | 71.78 Million USD | -16.64% |
| 2002 Q1 | 83.97 Million USD | -2.48% |
| 2002 Q3 | 67.01 Million USD | -14.75% |
| 2001 Q3 | 80.48 Million USD | -6.81% |
| 2001 Q4 | 86.1 Million USD | 6.99% |
| 2001 Q2 | 86.36 Million USD | 96.81% |
| 2001 Q1 | 43.88 Million USD | -2.94% |
| 2001 FY | 86.1 Million USD | 90.45% |
| 2000 FY | 45.21 Million USD | 59.76% |
| 2000 Q1 | 62.64 Million USD | 121.36% |
| 2000 Q3 | 50.74 Million USD | -7.77% |
| 2000 Q4 | 45.21 Million USD | -10.9% |
| 2000 Q2 | 55.01 Million USD | -12.18% |
| 1999 Q3 | 31.2 Million USD | 4.7% |
| 1999 Q4 | 28.3 Million USD | -9.29% |
| 1999 Q1 | 37.3 Million USD | 0.0% |
| 1999 FY | 28.3 Million USD | -24.13% |
| 1999 Q2 | 29.8 Million USD | -20.11% |
| 1998 FY | 37.3 Million USD | -42.44% |
| 1998 Q2 | 57 Million USD | 3.07% |
| 1998 Q4 | 37.3 Million USD | -17.84% |
| 1998 Q3 | 45.4 Million USD | -20.35% |
| 1998 Q1 | 55.3 Million USD | -14.66% |
| 1997 Q3 | 46.3 Million USD | 10.5% |
| 1997 Q4 | 64.8 Million USD | 39.96% |
| 1997 FY | 64.8 Million USD | 12.31% |
| 1997 Q2 | 41.9 Million USD | -15.86% |
| 1997 Q1 | 49.8 Million USD | -13.69% |
| 1996 Q1 | 40 Million USD | -2.2% |
| 1996 FY | 57.7 Million USD | 41.08% |
| 1996 Q3 | 57.1 Million USD | 16.29% |
| 1996 Q4 | 57.7 Million USD | 1.05% |
| 1996 Q2 | 49.1 Million USD | 22.75% |
| 1995 FY | 40.9 Million USD | -34.46% |
| 1995 Q4 | 40.9 Million USD | 3.28% |
| 1995 Q2 | 48.7 Million USD | -13.04% |
| 1995 Q1 | 56 Million USD | -10.26% |
| 1995 Q3 | 39.6 Million USD | -18.69% |
| 1994 Q4 | 62.4 Million USD | -11.99% |
| 1994 Q1 | 85.9 Million USD | -8.71% |
| 1994 Q2 | 78.6 Million USD | -8.5% |
| 1994 Q3 | 70.9 Million USD | -9.8% |
| 1994 FY | 62.4 Million USD | -33.69% |
| 1993 Q3 | 83.9 Million USD | -8.51% |
| 1993 Q2 | 91.7 Million USD | -9.3% |
| 1993 FY | 94.1 Million USD | -13.91% |
| 1993 Q1 | 101.1 Million USD | -7.5% |
| 1993 Q4 | 94.1 Million USD | 12.16% |
| 1992 FY | 109.3 Million USD | -29.16% |
| 1992 Q2 | 135.3 Million USD | -5.32% |
| 1992 Q4 | 109.3 Million USD | -8.07% |
| 1992 Q1 | 142.9 Million USD | -7.39% |
| 1992 Q3 | 118.9 Million USD | -12.12% |
| 1991 FY | 154.3 Million USD | 59.07% |
| 1991 Q3 | 158.3 Million USD | -4.47% |
| 1991 Q4 | 154.3 Million USD | -2.53% |
| 1991 Q1 | 87.5 Million USD | -9.79% |
| 1991 Q2 | 165.7 Million USD | 89.37% |
| 1990 Q3 | 100.2 Million USD | -5.2% |
| 1990 Q1 | 113.1 Million USD | 2.35% |
| 1990 FY | 97 Million USD | -12.22% |
| 1990 Q2 | 105.7 Million USD | -6.54% |
| 1990 Q4 | 97 Million USD | -3.19% |
| 1989 Q2 | 106.2 Million USD | 0.0% |
| 1989 Q3 | 104.8 Million USD | -1.32% |
| 1989 Q4 | 110.5 Million USD | 5.44% |
| 1989 FY | 110.5 Million USD | 100.91% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 84.255% |
| Alkermes plc | 2.13 Billion USD | 89.032% |
| Agenus Inc. | 313.91 Million USD | 25.361% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 93.882% |
| Aptorum Group Limited | 20.64 Million USD | -1035.174% |
| Ardelyx, Inc. | 297.57 Million USD | 21.264% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 69.395% |
| Bicycle Therapeutics plc | 595.34 Million USD | 60.644% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -217.903% |
| ChromaDex Corporation | 54.96 Million USD | -326.281% |
| Chimerix, Inc. | 212.77 Million USD | -10.117% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -728.727% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 46.867% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 89.491% |
| Precision BioSciences, Inc. | 159.78 Million USD | -46.639% |
| Dyadic International, Inc. | 8.21 Million USD | -2750.642% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -638.188% |
| Fortress Biotech, Inc. | 167.52 Million USD | -39.859% |
| Lantern Pharma Inc. | 43.64 Million USD | -436.801% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -45.225% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -1515.129% |
| Incyte Corporation | 6.78 Billion USD | 96.545% |
| IO Biotech, Inc. | 150.71 Million USD | -55.457% |
| Jaguar Health, Inc. | 50.76 Million USD | -361.559% |
| Novavax, Inc. | 1.85 Billion USD | 87.372% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 38.408% |
| Opthea Limited | 188.79 Million USD | -24.106% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 71.875% |
| ContextLogic Inc. | 423 Million USD | 44.61% |
| MiMedx Group, Inc. | 239.04 Million USD | 1.985% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -34.868% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -4432.196% |
| NextCure, Inc. | 129.41 Million USD | -81.042% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -334.309% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -537.918% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -625.368% |
| Vaxcyte, Inc. | 1.4 Billion USD | 83.358% |
| PDS Biotechnology Corporation | 59.39 Million USD | -294.512% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 63.422% |
| Pharming Group N.V. | 462.85 Million USD | 49.379% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -505.742% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 62.724% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1138.137% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1138.137% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -41.726% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -417.369% |
| Acelyrin, Inc. | 742.69 Million USD | 68.452% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -3457.279% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -3559.238% |
| Summit Therapeutics Inc. | 202.94 Million USD | -15.448% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -215.031% |
| Senti Biosciences, Inc. | 119.48 Million USD | -96.094% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -2.61% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -39.321% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -2735.544% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -4808.094% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 50.063% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -89.483% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 14.784% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 50.448% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -2218.664% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -9.228% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -20595.061% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 43.384% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1075.905% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 36.68% |
| MEI Pharma, Inc. | 41.37 Million USD | -466.286% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -623.017% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 31.249% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -99.873% |
| Fortress Biotech, Inc. | 167.52 Million USD | -39.859% |
| Precigen, Inc. | 151.04 Million USD | -55.122% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -588.756% |
| AlloVir, Inc. | 190.79 Million USD | -22.802% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 37.761% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 53.715% |
| ImmuCell Corporation | 43.8 Million USD | -434.835% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 63.916% |
| Onconetix, Inc. | 88.82 Million USD | -163.789% |
| PureTech Health plc | 693.97 Million USD | 66.238% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -139.854% |
| Elevation Oncology, Inc. | 89.09 Million USD | -162.991% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -3677.83% |
| Seer, Inc. | 436.26 Million USD | 46.294% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -187.144% |
| Innoviva, Inc. | 1.24 Billion USD | 81.158% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -76.934% |
| ESSA Pharma Inc. | 149.12 Million USD | -57.12% |
| GlycoMimetics, Inc. | 45.31 Million USD | -417.033% |
| GT Biopharma, Inc. | 14.1 Million USD | -1560.649% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 23.902% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 3.062% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 50.35% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -362.159% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -146.083% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -36997.127% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 58.629% |
| Aptose Biosciences Inc. | 12.92 Million USD | -1713.118% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -959.501% |
| Soligenix, Inc. | 9.79 Million USD | -2291.479% |
| Century Therapeutics, Inc. | 360.69 Million USD | 35.041% |
| Kura Oncology, Inc. | 448.93 Million USD | 47.81% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 13.907% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -1254.733% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -111.251% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -14.209% |
| Autolus Therapeutics plc | 375.38 Million USD | 37.583% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 6.889% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 34.034% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -376.881% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 64.561% |
| GRI Bio, Inc. | 2.95 Million USD | -7826.286% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -2109.298% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -37.408% |
| IGM Biosciences, Inc. | 423.41 Million USD | 44.663% |
| INmune Bio, Inc. | 57 Million USD | -311.047% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -5.301% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -179.125% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -797.126% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -3303.957% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -211.463% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -59.109% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -41.568% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 62.786% |
| Verastem, Inc. | 149.71 Million USD | -56.495% |
| Abeona Therapeutics Inc. | 64 Million USD | -266.084% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 54.252% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -51.693% |
| Histogen Inc. | 19.07 Million USD | -1128.443% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -934.434% |
| Surrozen, Inc. | 46.08 Million USD | -408.466% |
| Organovo Holdings, Inc. | 6.34 Million USD | -3590.361% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5337.959% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -62.679% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -1885.265% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -211.289% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -2650.254% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 35.449% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -1194.882% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 45.436% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -1757.804% |
| Apollomics, Inc. | 55.38 Million USD | -323.025% |
| Amarin Corporation plc | 831.68 Million USD | 71.828% |
| Mesoblast Limited | 669.15 Million USD | 64.985% |
| Turnstone Biologics Corp. | 112.81 Million USD | -107.686% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 59.306% |
| Synaptogenix, Inc. | 31.11 Million USD | -653.048% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -1823.022% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 57.249% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3889.962% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -3089.87% |
| Exelixis, Inc. | 2.94 Billion USD | 92.037% |
| Better Therapeutics, Inc. | 22.94 Million USD | -921.231% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 35.727% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 70.294% |
| NLS Pharmaceutics AG | 1.84 Million USD | -12587.956% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -2836.605% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -1494.427% |
| Gritstone bio, Inc. | 177.76 Million USD | -31.801% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -145.65% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -1211.709% |
| Avid Bioservices, Inc. | 336.55 Million USD | 30.383% |
| Insmed Incorporated | 1.32 Billion USD | 82.381% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -2333.45% |
| MediWound Ltd. | 66.45 Million USD | -252.55% |
| OmniAb, Inc. | 401.98 Million USD | 41.714% |
| Alector, Inc. | 621.82 Million USD | 62.321% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 34.662% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -4256.657% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -313.288% |
| Zai Lab Limited | 1.03 Billion USD | 77.391% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 51.03% |
| Aura Biosciences, Inc. | 255.07 Million USD | 8.144% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 68.761% |
| Immunic, Inc. | 54.29 Million USD | -331.502% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 11.991% |
| Veracyte, Inc. | 1.13 Billion USD | 79.408% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -1881.776% |
| FibroGen, Inc. | 423.52 Million USD | 44.679% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6569.542% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -4846.602% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -4215.35% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 97.944% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -2560.999% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 54.72% |
| TG Therapeutics, Inc. | 329.58 Million USD | 28.911% |
| Galecto, Inc. | 38.22 Million USD | -512.92% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -717.063% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 94.623% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 0.469% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -843.165% |
| XBiotech Inc. | 227.24 Million USD | -3.106% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -145.65% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -64.306% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 18.053% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -83.235% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 38.664% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 84.286% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 35.78% |
| Vaxxinity, Inc. | 44.35 Million USD | -428.264% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 54.677% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -1159.051% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 23.193% |
| NexImmune, Inc. | 8.59 Million USD | -2626.349% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -2086.625% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -1267.99% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.292% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -957.738% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -59630.284% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -35.177% |
| Ainos, Inc. | 31.84 Million USD | -635.828% |
| Pluri Inc. | 39.52 Million USD | -492.762% |
| Prothena Corporation plc | 696.38 Million USD | 66.355% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 17.096% |
| Celularity Inc. | 143.88 Million USD | -62.835% |
| Rallybio Corporation | 115.62 Million USD | -102.647% |
| Cue Biopharma, Inc. | 61.53 Million USD | -280.791% |
| MeiraGTx Holdings plc | 458.16 Million USD | 48.861% |
| Omeros Corporation | 378.26 Million USD | 38.06% |
| Humacyte, Inc. | 128.22 Million USD | -82.729% |
| Immunocore Holdings plc | 597 Million USD | 60.754% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -649.547% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -241.896% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 77.67% |
| CalciMedica, Inc. | 12.18 Million USD | -1822.864% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 7.628% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -37.092% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 24.671% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 58.553% |
| Pulmatrix, Inc. | 33.95 Million USD | -589.973% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -763.114% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -66.338% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 81.99% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -79.97% |
| Cytokinetics, Incorporated | 824.31 Million USD | 71.576% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -1009.222% |
| Nutriband Inc. | 7.51 Million USD | -3016.884% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -196.756% |
| Vor Biopharma Inc. | 209.82 Million USD | -11.663% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 96.756% |
| Evogene Ltd. | 51.1 Million USD | -358.506% |
| ProKidney Corp. | 420.55 Million USD | 44.287% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -327.299% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -2361.073% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 57.118% |
| CorMedix Inc. | 82.05 Million USD | -185.524% |
| BioLineRx Ltd. | 63.92 Million USD | -266.525% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 41.798% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -730.855% |
| Atai Life Sciences N.V. | 293.47 Million USD | 20.164% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -43.629% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -83.884% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 58.311% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -142.249% |
| MediciNova, Inc. | 66.26 Million USD | -253.555% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -166.409% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -5150.601% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2423.92% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 60.169% |
| Biomea Fusion, Inc. | 199.92 Million USD | -17.193% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 87.689% |
| Mereo BioPharma Group plc | 66.49 Million USD | -252.338% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 51.7% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 61.77% |
| Absci Corporation | 234.48 Million USD | 0.076% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -3103.021% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 31.066% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -41.93% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 55.483% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 15.626% |
| Allakos Inc. | 243.61 Million USD | 3.821% |
| Imunon, Inc. | 21.91 Million USD | -968.986% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 9.078% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 62.302% |
| BioAtla, Inc. | 119.65 Million USD | -95.809% |
| NLS Pharmaceutics AG | 1.84 Million USD | -12587.956% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -7176.429% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 63.552% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -144.229% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -5.906% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -86.184% |
| aTyr Pharma, Inc. | 122.06 Million USD | -91.945% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -52.239% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 59.622% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 52.225% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -112.097% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -1445.77% |
| Akari Therapeutics, Plc | 4.35 Million USD | -5280.046% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1275.221% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 86.482% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7497.343% |
| UroGen Pharma Ltd. | 178.31 Million USD | -31.4% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 50.227% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -42062.079% |
| Orgenesis Inc. | 14.55 Million USD | -1510.095% |
| Entera Bio Ltd. | 11.76 Million USD | -1891.509% |
| GH Research PLC | 226.3 Million USD | -3.536% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -328.385% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -118.084% |
| Xencor, Inc. | 952.69 Million USD | 75.406% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -2910.122% |
| Replimune Group, Inc. | 487.72 Million USD | 51.96% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -2802.966% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 63.867% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7497.343% |
| Portage Biotech Inc. | 7.77 Million USD | -2911.968% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -5150.601% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 15.398% |
| OncoCyte Corporation | 74.89 Million USD | -212.852% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -11423.484% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -3948.997% |
| Purple Biotech Ltd. | 44.3 Million USD | -428.872% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -586.576% |
| scPharmaceuticals Inc. | 94.47 Million USD | -147.993% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -1198.429% |
| HilleVax, Inc. | 344.43 Million USD | 31.975% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -7277.236% |
| Tharimmune, Inc. | 10.94 Million USD | -2040.44% |
| Genprex, Inc. | 10.67 Million USD | -2095.764% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 52.78% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -143.425% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -9557.914% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -5524.879% |
| OKYO Pharma Limited | 1.54 Million USD | -15101.873% |
| Savara Inc. | 177.56 Million USD | -31.953% |
| Curis, Inc. | 77.28 Million USD | -203.177% |
| Daré Bioscience, Inc. | 21.28 Million USD | -1000.924% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -266.388% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -2797.613% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1109.545% |
| BeiGene, Ltd. | 5.8 Billion USD | 95.964% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -1825.392% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 88.782% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 34.544% |
| Erasca, Inc. | 395.29 Million USD | 40.728% |
| bluebird bio, Inc. | 619.16 Million USD | 62.158% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5319.408% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.575% |
| DBV Technologies S.A. | 182.98 Million USD | -28.043% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5319.408% |
| Moderna, Inc. | 18.42 Billion USD | 98.728% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -1186.167% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -1922.277% |
| Molecular Templates, Inc. | 35.38 Million USD | -562.185% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -69.458% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 70.301% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 22.865% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -125.406% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 49.681% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 25.248% |
| MacroGenics, Inc. | 306.82 Million USD | 23.636% |
| RenovoRx, Inc. | 1.46 Million USD | -15882.333% |
| Adicet Bio, Inc. | 207.29 Million USD | -13.028% |
| Prime Medicine, Inc. | 193.85 Million USD | -20.867% |
| Aditxt, Inc. | 44.57 Million USD | -425.594% |
| Adagene Inc. | 115.72 Million USD | -102.457% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -5160.239% |
| Quantum-Si incorporated | 298.25 Million USD | 21.441% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 84.248% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -2939.269% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 33.301% |
| SciSparc Ltd. | 11.18 Million USD | -1995.341% |
| Vericel Corporation | 353.65 Million USD | 33.749% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1818.517% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -311.772% |
| Generation Bio Co. | 374.75 Million USD | 37.479% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 7.997% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -47.762% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 31.363% |
| Invivyd, Inc. | 229.18 Million USD | -2.234% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 72.239% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -1825.345% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -28.462% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1047.185% |
| 2seventy bio, Inc. | 565.42 Million USD | 58.562% |
| ADMA Biologics, Inc. | 329.18 Million USD | 28.823% |
| Clene Inc. | 52.34 Million USD | -347.643% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -298.917% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -80.379% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2423.92% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 64.158% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -126.135% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -79.698% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -140.181% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -230.015% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 3.402% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 88.046% |
| Evaxion Biotech A/S | 12.88 Million USD | -1717.891% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 7.046% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 68.871% |
| Trevena, Inc. | 40.6 Million USD | -477.025% |
| Surrozen, Inc. | 46.08 Million USD | -408.466% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -3.739% |
| Cingulate Inc. | 3.49 Million USD | -6610.734% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -1308.99% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -256.677% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -1905.207% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 12.743% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 68.716% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -86.113% |
| Clearmind Medicine Inc. | 4.32 Million USD | -5318.13% |
| Kronos Bio, Inc. | 213.27 Million USD | -9.857% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -46.636% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2636.966% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 36.416% |
| Statera Biopharma, Inc. | 21.16 Million USD | -1006.776% |
| ImmunityBio, Inc. | 504.45 Million USD | 53.553% |
| Korro Bio, Inc. | 221.66 Million USD | -5.701% |
| Kineta, Inc. | 10.28 Million USD | -2178.971% |
| BioVie Inc. | 25.2 Million USD | -829.458% |
| Codexis, Inc. | 136.56 Million USD | -71.572% |
| Celularity Inc. | 143.88 Million USD | -62.835% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 63.123% |
| Celcuity Inc. | 191.21 Million USD | -22.53% |
| Virax Biolabs Group Limited | 5.48 Million USD | -4172.471% |
| Cibus, Inc. | 544.41 Million USD | 56.962% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -86.11% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1040.484% |
| IN8bio, Inc. | 33.7 Million USD | -595.07% |
| Kodiak Sciences Inc. | 479.37 Million USD | 51.123% |
| Annexon, Inc. | 297.67 Million USD | 21.289% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -35.426% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -70.439% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -1016.091% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 92.164% |
| Eyenovia, Inc. | 28.77 Million USD | -714.128% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1.637% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -3143.369% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -284.567% |
| Arcellx, Inc. | 825.13 Million USD | 71.604% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -187.003% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 49.316% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -661.954% |
| Moolec Science SA | 24.05 Million USD | -874.172% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 24.449% |
| Geron Corporation | 394.07 Million USD | 40.544% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -130.362% |
| Royalty Pharma plc | 16.38 Billion USD | 98.57% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 60.62% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -3249.638% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -1848.074% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -3.645% |
| Humacyte, Inc. | 128.22 Million USD | -82.729% |
| Structure Therapeutics Inc. | 482.01 Million USD | 51.392% |
| 89bio, Inc. | 596.26 Million USD | 60.705% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 7.079% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -12564.919% |
| Genelux Corporation | 27.89 Million USD | -739.999% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -162.073% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -2.124% |
| Notable Labs, Ltd. | 19.54 Million USD | -1099.023% |
| Liquidia Corporation | 120.43 Million USD | -94.552% |
| Mustang Bio, Inc. | 17.74 Million USD | -1220.601% |
| Immunovant, Inc. | 666.71 Million USD | 64.857% |
| Quantum-Si incorporated | 298.25 Million USD | 21.441% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -62.257% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -332.609% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -33.47% |
| Acasti Pharma Inc. | 73.3 Million USD | -219.647% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -5046.892% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -797.126% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 75.715% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -4414.541% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -928.493% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -354.045% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -29.669% |
| PepGen Inc. | 143.05 Million USD | -63.787% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -513.081% |
| United Therapeutics Corporation | 7.16 Billion USD | 96.731% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1121.272% |
| Solid Biosciences Inc. | 164.93 Million USD | -42.053% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3889.962% |
| Immuneering Corporation | 102.58 Million USD | -128.398% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5337.959% |
| Silo Pharma, Inc. | 7.74 Million USD | -2924.745% |
| Belite Bio, Inc | 94.64 Million USD | -147.566% |
| XOMA Corporation | 234.3 Million USD | 0.0% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -0.477% |
| Bionomics Limited | 27.64 Million USD | -747.409% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 41.63% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -118.182% |
| uniQure N.V. | 831.68 Million USD | 71.828% |
| Cassava Sciences, Inc. | 151.66 Million USD | -54.488% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -5160.239% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 14.453% |
| Forte Biosciences, Inc. | 38.98 Million USD | -501.08% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -5652.38% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -536.152% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -3143.369% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6569.542% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -1882.074% |
| Altimmune, Inc. | 210.64 Million USD | -11.233% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 69.88% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -118.182% |
| Compugen Ltd. | 121.33 Million USD | -93.104% |
| Peak Bio, Inc. | 2.59 Million USD | -8924.02% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -35.963% |
| Benitec Biopharma Inc. | 52.21 Million USD | -348.767% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 31.463% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -573.802% |
| Zura Bio Limited | 100.84 Million USD | -132.342% |
| PolyPid Ltd. | 15.37 Million USD | -1424.206% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -96.42% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -573.802% |
| Instil Bio, Inc. | 325.63 Million USD | 28.047% |
| argenx SE | 4.54 Billion USD | 94.842% |
| Immunome, Inc. | 148.54 Million USD | -57.736% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -49.355% |
| Verona Pharma plc | 308.12 Million USD | 23.959% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -169.438% |
| Shattuck Labs, Inc. | 159.56 Million USD | -46.838% |
| CervoMed Inc. | 9.97 Million USD | -2249.466% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -24.327% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -1957.438% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -30.599% |
| Moolec Science SA | 24.05 Million USD | -874.172% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -3730.025% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -35.478% |
| AnaptysBio, Inc. | 452.38 Million USD | 48.208% |
| Design Therapeutics, Inc. | 289.64 Million USD | 19.107% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -221.732% |
| NeurAxis, Inc. | 509.49 Thousand USD | -45886.638% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -4224.492% |
| Lumos Pharma, Inc. | 40.63 Million USD | -476.556% |
| Achilles Therapeutics plc | 161.45 Million USD | -45.118% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -169.438% |
| 180 Life Sciences Corp. | 5.25 Million USD | -4354.835% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -232.683% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2636.966% |
| Nutriband Inc. | 7.51 Million USD | -3016.884% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 8.004% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -17.561% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -207.433% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -304.553% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 55.502% |
| Palisade Bio, Inc. | 14.05 Million USD | -1567.385% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -11.415% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 83.949% |
| Neurogene Inc. | 222.57 Million USD | -5.269% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 63.765% |
| AEON Biopharma, Inc. | 6.84 Million USD | -3322.951% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 48.282% |
| Sesen Bio, Inc. | 189.17 Million USD | -23.855% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 13.818% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -1608.746% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 69.975% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 12.245% |
| Athira Pharma, Inc. | 160.24 Million USD | -46.214% |
| Vaccinex, Inc. | 3.63 Million USD | -6352.795% |
| HCW Biologics Inc. | 28.51 Million USD | -721.715% |
| XOMA Corporation | 234.3 Million USD | 0.0% |
| Nektar Therapeutics | 398.03 Million USD | 41.135% |
| Arvinas, Inc. | 1.3 Billion USD | 82.04% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1275.221% |
| Merus N.V. | 458.49 Million USD | 48.898% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -14.648% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -30.02% |
| Rezolute, Inc. | 132.73 Million USD | -76.515% |
| Clene Inc. | 52.34 Million USD | -347.643% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -1469.974% |
| BeyondSpring Inc. | 24.8 Million USD | -844.457% |
| Synlogic, Inc. | 75.55 Million USD | -210.127% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -1875.223% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -2402.147% |
| Peak Bio, Inc. | 2.59 Million USD | -8924.02% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -34.014% |
| Krystal Biotech, Inc. | 818.35 Million USD | 71.369% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 2.552% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 67.718% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -6449.891% |
| MannKind Corporation | 475.19 Million USD | 50.694% |
| Ikena Oncology, Inc. | 192.09 Million USD | -21.973% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -1651.914% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -101.049% |
| Gossamer Bio, Inc. | 311.91 Million USD | 24.883% |
| CohBar, Inc. | 16.36 Million USD | -1331.662% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -566.328% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -3103.021% |
| Legend Biotech Corporation | 1.84 Billion USD | 87.326% |
| Mural Oncology plc | 301.74 Million USD | 22.351% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -650.604% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -4024.724% |
| Disc Medicine, Inc. | 367.99 Million USD | 36.331% |
| Champions Oncology, Inc. | 26.13 Million USD | -796.606% |
| REGENXBIO Inc. | 573.97 Million USD | 59.179% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -8551.907% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -51.763% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -1840.288% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 31.095% |
| Vaxart, Inc. | 91.83 Million USD | -155.146% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -291.128% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -57.963% |
| Cellectis S.A. | 334.27 Million USD | 29.907% |
| Longeveron Inc. | 12.17 Million USD | -1823.969% |
| Repare Therapeutics Inc. | 253.9 Million USD | 7.72% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 92.823% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -16.656% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 88.782% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -14318.523% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 15.631% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -43.657% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -68.873% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -818.035% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.969% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 79.695% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1818.517% |
| Veru Inc. | 50.59 Million USD | -363.083% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -414.348% |
| Cingulate Inc. | 3.49 Million USD | -6610.734% |
| Passage Bio, Inc. | 150.54 Million USD | -55.635% |
| Context Therapeutics Inc. | 16.06 Million USD | -1358.662% |
| Exicure, Inc. | 11.58 Million USD | -1923.325% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 37.694% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -44.951% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -1241.008% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 29.585% |
| Nuvalent, Inc. | 732.38 Million USD | 68.008% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -1467.852% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -161.631% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -1551.053% |
| OmniAb, Inc. | 401.98 Million USD | 41.714% |
| Anew Medical, Inc. | 19.45 Million USD | -1104.264% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -776.66% |
| Lipocine Inc. | 23 Million USD | -918.653% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -67.589% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 23.322% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -179.125% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -92.777% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -2852.754% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 73.444% |
| Ocugen, Inc. | 64.54 Million USD | -262.993% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -88.132% |
| Q32 Bio Inc. | 306.11 Million USD | 23.461% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -5467.99% |
| Alumis Inc. Common Stock | 89.61 Million USD | -161.462% |
| Equillium, Inc. | 50.53 Million USD | -363.687% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -211.591% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -467.679% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -13675.5% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -796.297% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -263.59% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -6186.394% |
| Dominari Holdings Inc. | 57.55 Million USD | -307.069% |
| Edesa Biotech, Inc. | 8.89 Million USD | -2535.427% |
| vTv Therapeutics Inc. | 11.01 Million USD | -2026.529% |
| Bio-Techne Corporation | 2.81 Billion USD | 91.671% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 74.998% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 71.126% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 15.617% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -461.846% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 64.903% |
| Nkarta, Inc. | 378.88 Million USD | 38.16% |
| BioCardia, Inc. | 2.98 Million USD | -7744.024% |
| Iterum Therapeutics plc | 26.25 Million USD | -792.269% |